RE:RE:Generic version of Pfizer's CDK4,6 inhibitor launched More M&A
Bibhash Mukhopadhyay, managing partner of venture capital fund Sound Bioventures, anticipated “an uptick in M&A and partnering in general, at all levels of capital spend (few millions to multi-billions), all across the biotech ‘food chain’.” He noted that the decline in the number and value of deals in 2022 had created “pent-up demand in 2023.” He thought there would be a “fertile environment for both large ticket M&A (Alexion/AstraZeneca -type deals) and scientific partnering activities,” adding that large pharma and biotech would “eye acquiring commercial franchises that will be EPS [earnings per share] accretive.”
“M&A continues to be a focus – the drive to acquire impressive pipeline opportunities that can impact patient communities,” observed Gil Bashe, managing partner, chair global health at Finn Partners and a member of the incubators, accelerators and equity committee of the Prix Galien Award. “Many companies are sitting on vast sums of capital. While the economic tumult will lead some to watch their cash flow, others will see this as an opportunity to jump in and acquire. Biopharma has seen this before and M&A will be hot.”
[This at a time when ONCY's Immune Molecule Technology Platform pelareorep is "Phase 3 ready" with the potential for an accelerated approval that will immediately make any acquisition of ONCY accretive. ]